Filtros de búsqueda

Lista de obras de Simona Soverini

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia

artículo científico publicado en 2015

A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia

artículo científico publicado en 2011

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

artículo científico publicado en 2016

ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis

artículo científico

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

article by Simona Soverini et al published 20 June 2005 in Journal of Clinical Oncology

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

artículo científico publicado en 2006

Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop

artículo científico

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis

artículo científico

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

artículo científico publicado en 2011

Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation

artículo científico publicado en 2008

Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.

artículo científico publicado en 2012

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

artículo científico publicado en 2012

Aurora kinase inhibitors: which role in the treatment of chronicmyelogenous leukemia patients resistant to imatinib?

artículo científico publicado en 2009

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

artículo científico publicado en 2011

BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

artículo científico publicado en 2020

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

artículo científico publicado en 2014

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

artículo científico publicado en 2012

BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia

artículo científico publicado en 2013

Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model

artículo científico publicado en 2012

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

artículo científico publicado en 2016

CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.

artículo científico publicado en 2011

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.

artículo científico publicado en 2015

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia

artículo científico publicado en 2017

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

artículo científico publicado en 2011

Chromothripsis in acute myeloid leukemia: biological features and impact on survival.

artículo científico publicado en 2018

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2012

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

artículo científico publicado en 2018

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

artículo científico publicado en 2011

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.

artículo científico publicado en 2016

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients

artículo científico publicado en 2016

Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients.

artículo científico publicado en 2006

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

artículo científico publicado en 2006

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

artículo científico publicado en 2015

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

artículo científico publicado en 2017

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

artículo científico publicado en 2014

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

artículo científico publicado en 2003

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

artículo científico publicado en 2011

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

artículo científico publicado en 2004

Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.

artículo científico publicado en 2009

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

artículo científico publicado en 2004

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t

scientific article published on 30 December 2013

Dual tyrosine kinase inhibitors in chronic myeloid leukemia.

artículo científico publicado en 2005

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib

scientific article published on 01 October 2011

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

artículo científico publicado en 2009

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

artículo científico publicado en 2013

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

artículo científico publicado en 2008

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib

scientific article published on 12 April 2011

FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage

artículo científico publicado en 2017

First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy

artículo científico publicado en 2006

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

artículo científico publicado en 2004

Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutations.

artículo científico publicado en 2012

IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis

artículo científico publicado en 2010

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia

artículo científico publicado en 2012

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

artículo científico publicado en 2009

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute

artículo científico publicado en 2009

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method

article published in 2008

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

artículo científico publicado en 2004

Imatinib mesylate for the treatment of chronic myeloid leukemia

artículo científico publicado en 2008

Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis

artículo científico publicado en 2018

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party

artículo científico publicado en 2007

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2009

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

artículo científico

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

artículo científico publicado en 2016

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

artículo científico publicado en 2017

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini

artículo científico publicado en 2012

Interferon in CML: back to the past, or towards the future?

artículo científico publicado en 2015

Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.

artículo científico publicado en 2009

Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy

artículo científico publicado en 2008

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

scientific article published on 01 February 2014

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

artículo científico publicado en 2015

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

artículo científico publicado en 2008

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

artículo científico publicado en 2011

Molecular monitoring

artículo científico publicado en 2014

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor

artículo científico

Molecular response in CML: where is the bar?

artículo científico publicado en 2014

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

artículo científico publicado en 2003

Molecular therapy for multiple myeloma.

artículo científico publicado en 2001

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio.

artículo científico publicado en 2007

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

artículo científico publicado en 2006

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management

artículo científico publicado en 2006

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia

artículo científico

New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia

scientific article published on June 2009

New targets for Ph+ leukaemia therapy

scientific article published on September 2009

New tyrosine kinase inhibitors in chronic myeloid leukemia.

artículo científico publicado en 2005

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2014

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

scientific article published on 05 December 2019

Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper

scientific article published on 10 March 2020

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

artículo científico publicado en 2016

Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia

artículo científico publicado en 2021

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia

article

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation.

artículo científico publicado en 2009

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

artículo científico publicado en 2007

Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis

scientific journal article

Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one

artículo científico publicado en 2002

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

artículo científico publicado en 2009

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

artículo científico publicado en 2010

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

artículo científico publicado en 2009

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case

artículo científico publicado en 2017

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

artículo científico publicado en 2006

Present and future of molecular monitoring in chronic myeloid leukaemia

artículo científico publicado en 2016

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

artículo científico publicado en 2020

Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia

artículo científico publicado en 2010

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

artículo científico publicado en 2003

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2013

Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia

artículo científico publicado en 2001

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

artículo científico publicado en 2007

Response definitions and European Leukemianet Management recommendations

artículo científico publicado en 2009

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

artículo científico publicado en 2009

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

article by Simona Soverini et al published March 2007 in Lancet Oncology Commission

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

artículo científico publicado en 2009

Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant).

artículo científico publicado en 2015

Targeted therapy and the T315I mutation in Philadelphia-positive leukemias

scientific article published on 01 April 2007

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

artículo científico publicado en 2017

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

artículo científico publicado en 2013

The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party

artículo científico publicado en 2010

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report

artículo científico publicado en 2017

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

artículo científico publicado en 2007

The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.

artículo científico publicado en 2014

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges

article published in 2019

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

artículo científico publicado en 2009

Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.

artículo científico publicado en 2009

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

artículo científico publicado en 2013

Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response

artículo científico publicado en 2014

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.

artículo científico publicado en 2007

What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?

artículo científico publicado en 2016

c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration

artículo científico publicado en 2010

c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells.

artículo científico publicado en 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda